Dr. Reddy’s announces the Launch of Amlodipine Besylate and Atorvastatin Calcium Tablets
Hyderabad, India, March 27, 2014
Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched Amlodipine Besylate and Atorvastatin Calcium Tablets 2.5/10mg, 2.5/20mg, 2.5/40mg, 5/10mg, 5/20mg, 5/40mg, 5/80mg, 10/10mg, 10/20mg, 10/40mg and 10/80 mg a therapeutic equivalent generic version of CADUET® (amlodipine Besylate and atorvastatin calcium) tablets, in the US market on March 17, 2014, following the approval by the United States Food & Drug Administration (USFDA).
The CADUET® tablets brand and generic had U.S. sales of approximately $163 Million MAT for the most recent twelve months ending in January 2014 according to IMS Health*.
Dr. Reddy’s Amlodipine Besylate and Atorvastatin Calcium Tablets are available in bottle counts of 30 and 90**.
This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.
About Dr. Reddy’s
Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Major therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infective. Major markets include India, USA, Russia-CIS and Europe apart from other select geographies within Emerging Markets. For more information, log on to:
CADUET® is a registered trademark of Pfizer Inc.
*IMS National Sales Perspectives: Retail and Non-Retail MAT January 2014
**available for select strengths only
For more information please contact:
Investors and Financial Analysts:
Kedar Upadhye at email@example.com / +91-40-66834297
Saunak Savla at firstname.lastname@example.org / +91-40-49002135
Milan Kalawadia (USA) at email@example.com / +1 609-375-9831
SVS Chowdary at firstname.lastname@example.org / +91-40-49002448